Cytosorbents outlines early 2027 DrugSorb-ATR De Novo plan with $300M initial U.S./Canada market

Earnings Call Insights: Cytosorbents Corporation (CTSO) Q3 2026

Management view

• "We set a clear objective to reach operating cash flow breakeven in the second half of 2026. I'm pleased to report that we achieved that objective in the third quarter, excluding restructuring-related

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.